Pharmacotherapy of cervical cancer

Bibliography

• Thun MJ, DeLancey JO, Center MM, The global burden of cancer:priorities for prevention. Carcinogenesis 2010;31(1):100-10
   PubMedGoogle Scholar
• Long HJ III. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007;25:2966-74
   PubMedGoogle Scholar
• Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009;36(2):177-80
   Google Scholar
• Serkies K, Jassem J. Chemotherapy in the primary treatment of cervical carcinoma. Crit Rev Oncol Hematol 2005;54:197-208
   PubMedGoogle Scholar
• Ercoli A, Iannone V, Legge F, Advances in surgical management of cervical cancer. Min Ginecol 2009;61(3):227-37
   PubMedGoogle Scholar
• Green JA, Kirwan JJ, Tierney J, Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix [review]. Cochrane Database Syst Rev 2009;4:1-52
   Google Scholar
• Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003;39(17):2470-86
   PubMedGoogle Scholar
• Ferrandina G, Legge F, Fagotti A, Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol 2007;107(1 Suppl 1):S127-32
   PubMed Web of Science ®Google Scholar
• Dargent D, Martin X, Sacchettoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000;88:1877-82
   PubMedGoogle Scholar
• Landoni F, Parma G, Peiretti M, Chemoconization in early cervical cancer. Gynecol Oncol 2007;107:S125-S2
   PubMedGoogle Scholar
• Maneo A, Chiari S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol 2008;111:438-43
   PubMed Web of Science ®Google Scholar
• Rosa DD, Medeiros LR, Edelweiss MI, Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 2009;3:CD005342
   Google Scholar
• Rogers L, Siu SS, Luesley D, Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer. Cochrane Database Syst Rev 2009;4:CD007583
   Google Scholar
• Peters WA III, Liu PY, Barrett RJ II, Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18(8):1606-13
   PubMedGoogle Scholar
• Keys HM, Bundy BN, Stehman FB, Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340(15):1154-61
   PubMedGoogle Scholar
• Morris M, Eifel PJ, Lu J, Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340(15):1137-43
   PubMedGoogle Scholar
• Rose PG, Bundy BN, Watkins EB, Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;15:1144-53
   Google Scholar
• Whitney CW, Sause W, Bundt BN, Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-48
   PubMed Web of Science ®Google Scholar
• Green JA, Kirwan JM, Tierney JF, Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781–6
   PubMed Web of Science ®Google Scholar
• Vale C, Tierney JF, Stewart LA, Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. J Clin Oncol 2008;26(35):5802-12
   PubMedGoogle Scholar
• Wong LC, Ngan HY, Cheung AN, Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17(7):2055-60
   PubMedGoogle Scholar
• Available from: www.clinicaltrials.org
   Google Scholar
• Duenas-Gonzalez A, Zarba JJ, Alcedo JC, A Phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. Meeting abstracts. J Clin Oncol 2009;27:18S
   Google Scholar
• Lanciano R, Calkins A, Bundy BN, Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(33):8289-95
   PubMedGoogle Scholar
• Domingo E, Lorvidhaya V, de Los Reyes R, Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results. Oncologist 2009;14(8):828-34
   PubMedGoogle Scholar
• Bhatt ML, Matin A, Srivastava MC, Evaluation of gemcitabine versus cisplatinum as an adjunct to radiotherapy in locally advanced carcinoma uterine cervix. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):16012
   Google Scholar
• Lorvidhaya V, Chitapanaraux I, Sangruchi S, Concurrent mytomicin C. 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcionoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55(5):1226-32
   PubMedGoogle Scholar
• Benedetti-Panici P, Greggi S, Scambia G, Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 1998;34(3):341-6
   PubMedGoogle Scholar
• Buda A, Fossati R, Colombo N, Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005;23(18):4137-45
   PubMedGoogle Scholar
• Basile S, Angioli R, Manci N, Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. Int J Gynecol Cancer 2006;16(4):1491-7
   PubMedGoogle Scholar
• Eddy GL, Manetta A, Alvarez RD, Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1995;57(3):412-6
   PubMedGoogle Scholar
• Chang TC, Lai CH, Hong JH, Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 2000;18(8):1740-7
   PubMedGoogle Scholar
• Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol 2001;12(4):541-7
   PubMedGoogle Scholar
• Sugiyama T, Nishida T, Kumagai S, Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 1999;81(1):95-8
   PubMedGoogle Scholar
• Benedetti-Panici P, Greggi S, Colombo A, Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002;20(1):179-88
   PubMedGoogle Scholar
• Gonzalez-Martin A, Gonzalez-Cortijo L, Carballo N, The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecol Oncol 2008;110(3 Suppl 2):S36-40
   PubMedGoogle Scholar
• Eddy GL, Bundy BN, Creasman WT, Treatment of (‘bulky’) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol 2007;106(2):362-9
   PubMedGoogle Scholar
• Lissoni AA, Colombo N, Pellegrino A, A Phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 2009;20(4):660-5
   PubMedGoogle Scholar
• Resbeut M, Cowen D, Viens P, Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. Gynecol Oncol 1994;54(1):68-75
   PubMedGoogle Scholar
• Jurado M, Martinez-Monge R, García-Foncillas J, A Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecol Oncol 1999;74(1):30-7
   PubMedGoogle Scholar
• Mancuso S, Smaniotto D, Benedetti Panici P, Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 2000;78(3 Pt 1):324-8
   PubMedGoogle Scholar
• Houvenaeghel G, Lelievre L, Rigouard AL, Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecol Oncol 2006;102(1):74-9
   PubMedGoogle Scholar
• Lerouge D, Touboul E, Lefranc JP, Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion. Cancer Radiother 2004;8(3):168-77
   PubMedGoogle Scholar
• Classe JM, Rauch P, Rodier JF, Groupe des Chirurgiens de Centre de Lutte Contre le Cancer. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol 2006;102(3):523-9
   PubMedGoogle Scholar
• Eifel PJ, Winter K, Morris M, Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22(5):872-80
   PubMedGoogle Scholar
• Chassagne D, Sismondi P, Horiot JC, A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 1993;26(3):195-202
   PubMedGoogle Scholar
• Keys HM, Bundy BN, Stehman FM, Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003;89(3):343-53
   PubMedGoogle Scholar
• Thigpen T, Shingleton H, Homesley H, Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Crit Rev Oncol Hematol 2005;54(3):197-208
   PubMedGoogle Scholar
• Bonomi P, Blessin JA, Stehman FB, Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1985;3(8):1079-85
   PubMedGoogle Scholar
• Weiss GR, Green S, Hannigan EV, A Phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol 1990;39(3):332-6
   PubMedGoogle Scholar
• Arseneau J, Blessing JA, Stehman FB, McGehee R. A Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). Invest New Drugs 1986;4(2):187-91
   PubMedGoogle Scholar
• McGuire WP, Blessing JA, Moore D, Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group Study. J Clin Oncol 1996;14(3):792-5
   PubMedGoogle Scholar
• Kudelka AP, Winn R, Edwards CL, An update of a Phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997;8(7):657-61
   PubMedGoogle Scholar
• Curtin JP, Blessing JA, Webster KD, Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19(5):1275-8
   PubMedGoogle Scholar
• Verschraegen CF, Levy T, Kudelka AP, Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625-31
   PubMed Web of Science ®Google Scholar
• Look KY, Blessing JA, Levenback C, A phase II study of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1998;70(3):334-8
   PubMedGoogle Scholar
• Lhomme C, Fumoleau P, Fargeot P, Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17:3136-42
   PubMedGoogle Scholar
• Bookman MA, Blessing JA, Hanjani P, Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446–9
   PubMed Web of Science ®Google Scholar
• Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2001;81:213-5
   PubMed Web of Science ®Google Scholar
• Morris M, Brader KR, Levenback C, Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998;16:1094–8
   PubMedGoogle Scholar
• Lhomme C, Vermorken JB, Mickiewicz E, Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer 2000;36(2):194-9
   PubMedGoogle Scholar
• Muggia FM, Blessing JA, Waggoner S, Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a gynaecologic Oncology Group Study. Gynecol Oncol 2005;96(1):108-11
   PubMedGoogle Scholar
• Sutton GP, Blessing JA, McGuire WP, Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group Study. Am J Obstet Gynecol 1993;168:805–7
   PubMed Web of Science ®Google Scholar
• Garcia AA, Blessing JA, Darcy KM, Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynaecologic Oncology Group Study. Gynecol Oncol 2007;104(3):572-9
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Van le L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1998;70(2):263-6
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Buller RE, Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2003;89(2):267-70
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;102(2):210-3
   PubMedGoogle Scholar
• Miller DS, Blessing JA, Bodurka DC, Evaluation of pemetrexed (Alymta, LY231514) as as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110(1):65-70
   PubMedGoogle Scholar
• Lorusso D, Ferrandina G, Pignata S, Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010;21(1):61-6
   PubMedGoogle Scholar
• Omura GA, Blessing JA, Vaccarello L, Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1997;15(1):165–71
   PubMedGoogle Scholar
• Moore DH, Blessing JA, McQuellon RP, Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3113-19
   PubMed Web of Science ®Google Scholar
• Long HJ III, Bundy BN, Grendys EC Jr, Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33
   PubMed Web of Science ®Google Scholar
• Monk BJ, Huang HQ, Cella D, Long HJ III. Gynecologic Oncology Group study. Quality of life outcomes from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(21):4617–25
   PubMedGoogle Scholar
• Monk BJ, Sill MW, McMeekin DS, Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2009;27(28):4649-55
   PubMedGoogle Scholar
• Moore KN, Herzog TJ, Lewin S, A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105(2):299-303
   PubMedGoogle Scholar
• Mabuchi S, Morishige K, Fujita M, The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol 2009;113(2):200-4
   PubMedGoogle Scholar
• Saito I, Kitagawa R, Fukuda H, A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010;40(1):90-3
   PubMedGoogle Scholar
• Kuo Y, Blank S V, Kobrinsky B, Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer (CC): New York Cancer Consortium Trial P5840. Meeting abstracts. J Clin Oncol 2007;25:5549
   Google Scholar
• Buxton EJ, Meanwell CA, Hilton C, Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81(5):359-61
   PubMedGoogle Scholar
• Murad AM, Triginelli SA, Ribalta JC. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994;12(1):55-9
   PubMedGoogle Scholar
• Zanetta G, Fei F, Parma G, Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999;10(10):1171-4
   PubMedGoogle Scholar
• Stornes I, Mejlholm I, Jakobsen A. A Phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer. Gynecol Oncol 1994;55(1):123-5
   PubMedGoogle Scholar
• Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995;56(2):235-8
   PubMedGoogle Scholar
• Bloss JD, Blessing JA, Behrens BC, Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2002;20(7):1832-7
   PubMedGoogle Scholar
• Long HJ III, Monk BJ, Huang HQ, Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2006;100(3):537-43
   PubMedGoogle Scholar
• Tanioka M, Katsumata N, Hirata T, Secondary platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Meeting abstracts. J Clin Oncol 2009;27:5588
   Google Scholar
• Moore DH, Tian C, Monk BJ, Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010;116(1):44-9
   PubMedGoogle Scholar
• Symonds R, Davidson S, Chan S, SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):5548
   PubMedGoogle Scholar
• Tiersten AD, Selleck MJ, Hershman DL, Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004;92(2):635-8
   PubMedGoogle Scholar
• Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010;116(2):181-6
   PubMedGoogle Scholar
• Monk BJ, Sill MW, Burger RA, Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2009;27(7):1069-74
   PubMedGoogle Scholar
• Monk BJ, Mas L, Zarba JJ, A randomized Phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). Meeting abstracts. J Clin Oncol 2009;27:5520
   Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, A Phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116(2):163-7
   PubMedGoogle Scholar
• Del Campo JM, Prat A, Gil-Moreno A, Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008;110(3 Suppl 2):S72-6
   PubMedGoogle Scholar
• Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009;115:3166-80
   PubMedGoogle Scholar
• Available from: www.mito-group.it
   Google Scholar
• Farley H, Sill M, Walker JL, Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: a limited access phase II study of the Gynecologic Oncology Group. Meeting abstracts. J Clin Oncol 2009;27:5521
   Google Scholar
• Kurtz E, Besson D, Deslandres M, Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): a phase II GINECO Trial. Meeting abstracts. J Clin Oncol 2008;26:5512
   Google Scholar
• Goncalves A, Fabbro M, Lhomme C, A Phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008;108(1):42-6
   PubMedGoogle Scholar
• Schilder RJ, Sill MW, Lee YC, Mannel R. A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19(5):929-33
   PubMedGoogle Scholar
• Ferreira CG, Erlich F, Carmo CC, Erlotinib (E) combined with cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer: A Phase II trial. Meeting abstracts. J Clin Oncol 2008;26:5511
   PubMedGoogle Scholar